A panel of experts advising the U.S. Food and Drug Administration (FDA) voted to ease restrictions on multiple peptides, including the controversial BPC-157, known informally as the "Wolverine" peptide, despite concerns raised by the agency’s own scientific staff. The vote took place during a meeting of the FDA’s Pharmacy Compounding Advisory Committee in Maryland and marked a significant step toward broadening access to these substances, which are popular on social media and among biohackers, alternative medicine practitioners, and bodybuilders.
The committee voted eight to six in favor of removing prohibitions on BPC-157, a peptide that has drawn attention for its potential to reduce inflammation, aid muscle and tendon recovery, and accelerate fracture healing, based on preliminary animal and cellular studies. BPC-157, alongside peptides such as TB-500, KPV, Epitalon, and Semax, was among seven substances under review for deregulation to allow compounding pharmacies to manufacture them domestically. The panel rejected only one peptide, Emideltide, which was being considered for opioid withdrawal and sleep disorders.
FDA career scientists and officials urged caution, highlighting the limited clinical data supporting these peptides’ safety and effectiveness. They also noted a lack of standardized chemical descriptions, complicating quality control. The FDA has not approved any products containing BPC-157, which is also listed on the World Anti-Doping Agency’s prohibited list. The agency expressed concern about potential health risks, including ulcerative colitis, an inflammatory bowel disease. Experts questioned the consistency and contents of peptide formulations currently available on the gray market, primarily imported from China and sold online with disclaimers such as “for research use only.”
Critics of the vote argued that loosening restrictions without solid scientific backing could jeopardize patient safety. Public health advocates emphasized that the panel’s recommendation might be misinterpreted by the public as an official endorsement of clinical use. Some pointed to past incidents, including cases of severe adverse reactions linked to peptide injections at longevity conferences, to illustrate potential risks.
Supporters, including some pharmacists, physicians, and industry representatives, contend that legal pathways for compounded peptides would enable better quality control, patient safety monitoring, and collection of real-world data on efficacy and side effects. Health Secretary Robert F. Kennedy Jr. has been a prominent advocate for expanded peptide access, and some analysts suggest that political considerations played a role in the panel’s decision. The committee composition was altered recently to include members with potential industry ties, including pharmacists and doctors who may benefit from peptide sales. Tennessee state senator Bobby Harshbarger, who voted in favor of deregulation, is the son of Congresswoman Diana Harshbarger, an advocate of peptide use.
While the committee’s recommendation is influential, it is nonbinding; the FDA retains final authority. However, legal experts suggest that Secretary Kennedy may overrule FDA scientific objections, signaling a potential policy shift driven by political priorities. Industry stakeholders are closely monitoring the developments, anticipating a possible expansion of a market that Wall Street estimates could grow into a multibillion-dollar opportunity.
The unfolding regulatory debate highlights tensions between innovation, patient safety, scientific evidence, and political influence as the FDA navigates how to handle emerging therapies that have garnered significant public interest but remain insufficiently studied.